Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                FDA Voices

FDA Voices Home
          News & Events
          FDA Newsroom
          FDA Voices
          A Perspective on the FDA’s COVID-19 ResponseFDA Voices A Perspective on the FDA’s COVID-19 Response
  
  	
    Subscribe to Email Updates
    Share
    Post
    Linkedin

    Email
    PrintImage
              6 photos: FDA Commissioned Corps officers donning protecting gowns, gloves, masks and visors; 3D illustration of the coronavirus; cotton facemask; physician wearing medical gloves drawing vaccine or antiviral drug from vial with a syringe; closeup of blood in beaker labeled COVID-19 Positive; closeup of scientist preparing to examine sample under microscope*By: Mitch Zeller, Director, FDA Center for Tobacco Products*

I have the honor to run the FDA’s Center for Tobacco Products (CTP). While CTP’s work to protect the public health is essential and continues during the pandemic, we are the least involved of the FDA centers when it comes to working directly on the coronavirus (COVID-19) response. That said, I’ve been proud to join my FDA colleagues in our “all-hands-on-deck” approach to tackling this pandemic, lending as much support as possible as my FDA colleagues across the entire organization work tirelessly for the American people.

The COVID-19 pandemic represents a new and significant challenge for all of us – both personally and professionally. Despite these challenges and the impact on all of us, I am hopeful and inspired by what I see happening behind the scenes at the agency.

I’d like to offer my own perspective, from where I sit, on how the FDA is battling this pandemic. The FDA is integral in the fight against the coronavirus, using science and innovative approaches to take a broad range of actions that advance our nation’s response. As we proactively partner in new ways with our sister agencies and external partners, we are becoming more nimble, while maintaining our unwavering commitment to protecting the health of the American people. We continue to address any and all challenges that arise during this public health emergency including, for example, ensuring a safe food supply for humans and animals, working hard to facilitate access to diagnostics and moving forward the development of treatments and vaccines.

Dr. Mitch Zeller
Mitch ZellerI am privileged as a Center Director to see the hard work behind the scenes at the FDA. But I am keenly aware that the scope of the agency’s thoughtful deliberations is not always evident to external audiences. Nor, as regulators whose job it is to always follow the science, do our decisions always satisfy the broad array of external stakeholders. Those of us who work in CTP know what it’s like to be in the spotlight. Most recently, the distressing incidents of severe respiratory illness associated with use of vaping products, and the rise of youth use of e-cigarettes, put our work front and center. Yet regardless of the issue confronting the agency, the FDA team never loses sight of the need for science-based approaches to achieve an outcome that is most protective of public health. I can tell you how reassuring – and truly remarkable – it is to see the prolonged intense effort, attention and expertise the FDA is putting into the pandemic response.

For almost 40 years I’ve worked on FDA issues – as a public interest attorney, Congressional oversight counsel, foundation executive, consultant – and now for the last seven plus years in my second stint as an agency official. I’ve seen the FDA at its best, responding to unprecedented emergencies such as HIV/AIDS with both zeal and creativity. While the agency’s work on HIV/AIDS was a hallmark of compassion and commitment, what strikes me as being so imperative is that the agency remains steadfast in ensuring new diagnostics and therapies are safe and effective at all times – even in a pandemic.

The FDA I see today is clearly making a big difference, with thousands of highly-qualified staff and a team of dedicated, exemplary leaders working around the clock on the agency’s response. They are addressing every aspect of the crisis, from diagnostics to therapeutics to food safety and everything in between. The leaders at the FDA, starting at the top with Commissioner Hahn, represent the finest in public spirit and public service.

My peers on the leadership team are working nonstop with support from the most talented group of experts I have ever seen address a public health crisis at the FDA. My colleagues never lose sight of the need to move quickly and boldly yet are always mindful of the public health standards we are obligated to uphold in our statute. They are using every available method to move new treatments to patients as quickly as possible, while at the same time continuing to use a science-based, data-driven approach to determine whether they are helpful or harmful. The recent establishment of the Coronavirus Treatment Acceleration Program and its many features provide just one example of how the agency is employing rapid, interactive response efforts.

I also see how agency leadership is making sure to protect the safety of the FDA workforce. In the multiple conference calls I participate in every day as part of the outbreak response, FDA leaders continue to stress that the safety and well-being of staff is critical. In addition to maximizing telework, we have provided several flexibilities to our staff and significantly reduced the number of employees reporting to our campuses and buildings. And for those employees who are performing critical functions that cannot be done remotely, we are working to keep them as safe as possible. Our employees are our greatest asset and they never cease to amaze me with their steadfast dedication to our mission.

Going forward, we will be forever changed as citizens by what this pandemic has wrought. Personally, this will bring new perspective on what is important and essential in our lives, as we collectively and individually confront the pandemic’s life-changing impact. Professionally, we will find the time to assess the vital role we play as regulators. What should we do differently? What bedrock principles of consumer protection should remain unchanged? However we answer these questions, I am humbled and encouraged to know that the FDA has a strong, committed team that will continue to fulfill our critical public health mission that the American public counts so much on us to perform.

                                                                                  Content current as of:
      04/10/2020
              
              
Regulated Product(s)
		 Animal & Veterinary
			  			     			  			     Biologics
			     			  			     Drugs
			     			  			     Food & Beverages
			     			  			     Medical DevicesHealth Topic(s)
			  CoronavirusFDA Voices
 FDA Voices Email
                        Subscribe to receive FDA Voices email notifications.
    Enter your email address to subscribe:
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop